Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • Services & Support
  • Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
      • Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
    • Browse Research
    • Education Catalog
      • HLA and Search Strategy Resources
      • GVHD Interactive Provider Network Virtual Learning Series
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Early Complications
  • Vaccinations
  • Long-Term Care Guidelines
  • Chronic GVHD
  • Post-Transplant Guidelines

Chronic GVHD

  • Skin
  • Nails
  • Scalp and Body Hair
  • Eyes
  • Mouth
  • Lungs
  • Muscles, Fascia, Joints
  • Hematopoietic & Immune
  • GI Tract
  • Liver
  • Genitalia
  • Other
Research Spotlight
  • A safe and effective shared care approach after allogeneic HCT could be a new standard of care

    December 2022

  • New evidence based guidance to assist healthcare providers in helping patients return to work post transplant

    December 2022

  • Lack of collaborative relationships between physician teams associated with HCT care decisions

    April 2022

  • Post-Transplant Care
  • Chronic GVHD
  • Eyes
  • Email
  • Print This Page

Related Resources

  • Chronic GVHD Overview
  • Post-HCT Care Education
  • Long-Term Care Guidelines

Patient Resources

  • GVHD of the Eye (PDF)
  • Post-Bone Marrow Transplant Guidelines
  • Chronic GVHD Video

Screening Eyes for Chronic GVHD

Below are clinical manifestations that are potential early indicators of chronic GVHD of the eyes. If GVHD is suspected, timely collaboration with the patient's transplant center is recommended to confirm the diagnosis and to develop and evaluate a treatment plan.

These guidelines are based on published diagnostic criteria from the National Institutes of Health (NIH) Consensus Development Project on chronic GVHD. [1,2,3]

Clinical Examination

 
  • Visual inspection of the conjunctivae and sclerae
  • Ophthalmologic exam
 

Diagnostic Testing

 
  • Schirmer's tear test
  • Slit-lamp examination
 

Patient-Reported Symptoms and Signs

 
  • Dry, burning, gritty eyes
  • Itching
  • Orbital pain
  • Difficulty opening eyes in the morning
  • Sensitivity to light and wind
  • Excessive tearing
  • Diminished visual acuity and/or blurring
 

Possible Manifestations

 

New Onset Dry, Gritty, or Painful Eyes*

New ocular sicca documented by low Schirmer test values with a mean value of both eyes ≤ 5 mm of wetting at 5 minutes, but note that Schirmer’s test values are not useful for follow-up of ocular GVHD due to poor correlation with symptom change

Cicatricial Conjunctivitis*

Fibrous tissue scaring and inflammation

Keratoconjunctivitis Sicca (KCS)*

22-GHVD-keratoconjunctivitis.jpg

23-GHVD-keratoconjunctivitis.jpg

Inflammation of cornea and conjunctivae, with dryness, grittiness and/or orbital pain. Slit lamp exam with mean Schirmer's tear test values of 6 to 10 mm, not due to other causes

Confluent Areas of Punctate Keratopathy*

Closely spaced, non-inflamed pinpoint defects indicating loss of corneal epithelium, and observed with fluorescein staining

Photophobia**

Increased sensitivity to light

Periorbital Hyperpigmentation**

Excess pigmentation in the tissues surrounding or lining the orbit of the eye

Blepharitis**

24-GHVD-blepharitis.jpg

Erythema and edema of the eyelids and telangiectasia of lid margin  


Notes

* Distinctive but insufficient alone to establish an unequivocal diagnosis of chronic GVHD without further testing or additional organ involvement.

** Rare, controversial, or non-specific features of chronic GVHD.

*** Common in both acute and chronic GVHD.


References

  1. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015; 21(3): 389-401.  
  2. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015; 21(6): 984-999.  
  3. These guidelines have been developed by the National Marrow Donor Program® (NMDP)/Be The Match® in consultation with Sandra A. Mitchell, CRNP, MScN, AOCN; National Institutes of Health Clinical Center; and Steven Z. Pavletic, M.D.; National Cancer Institute, National Institutes of Health, Bethesda, Md. The information in this document does not represent the official position of the NIH or the U.S. Government.

Additional review from:

  • Dennis L. Confer, M.D., NMDP/Be The Match, Minneapolis, Minn.
  • Linda J. Burns, M.D., NMDP/Be The Match, Minneapolis, Minn. 
  • Madan Jagasia, M.D., Vanderbilt University Medical Center, Nashville, Tenn. 
  • Stephanie J. Lee, M.D., Fred Hutchinson Cancer Research Center, Seattle, Wash.

Text adapted from reports of the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease from Biology of Blood and Marrow Transplantation by American Society for Blood and Marrow Transplantation. Reproduced with permission of Elsevier, Inc.

Photo Credits

  • Photos/ Keratosis Pilaris; Lichen Planus-like; Hypopigmentation; Sclerosis; Erosion; Maculopapular: Maria L. Turner, M.D.; Edward W.Cowen, M.D.; Dermatology Branch, National Cancer Institute, NIH, Bethesda, Md.
  • Photos/ Poikiloderma; Morphea; Lichen Planus-like; Lichen Sclerosus-like; Hyperpigmentation; Sclerosis; Nail dystrophy; Alopecia; Edema: Edward W. Cowen, M.D.; Dermatology Branch, National Cancer Institute, NIH, Bethesda, Md.
  • Photos/ Lichen planus; Mucoceles; Erythema: Mark M. Schubert, D.D.S., M.S.D.; Fred Hutchinson Cancer Research Center, Seattle, Wash.
  • Photo/ Keratoconjunctivitis: Mary E.D. Flowers, M.D.; University of Washington, Seattle, Wash.
  • Photo/ Blepharitis: Janine A. Smith, M.D.; National Eye Institute, NIH, Bethesda, Md.

All photos used with permission.

  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Keep In Touch

  • Contact Us
  • Transplant Enews

Our Websites

  • Be The Match
  • Be The Match Mexico
  • Be The Match BioTherapies
  • CIBMTR
  • Jason Carter Clinical Trials Search
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright